Sign Up Today and Learn More About Immunis Stock
Invest in or calculate the value of your shares in Immunis or other pre-IPO companies through EquityZen's platform.
Immunis Stock
Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
About Immunis Stock
Founded
2018
Headquarters
Irvine, CA, US
Industries
Software, Data and Analytics, Artificial Intelligence
Immunis Press Mentions
Stay in the know about the latest news on Immunis
Immunis Appoints Dr. Christina Weng to its Advisory Board
businesswire • Jul 03, 2024
Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
businesswire • May 22, 2024
Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan
morningstar • Apr 07, 2024
Immunis Chairman Dr. Hans Keirstead to Speak at the Longevity Investors Lunch in Davos
businesswire • Jan 08, 2024
Immunis Chairman Dr. Hans Keirstead is Honored As One of OCBJ’s OC500
businesswire • Dec 21, 2023
Immunis Management
Leadership team at Immunis
Chief Artificial Intelligence Officer
Neil Sahota
Chairman of the Board of Directors
Hans Keirstead
Join now and verify your accreditation status to gain access to:
- Immunis current valuation
- Immunis stock price
- Available deals in Immunis and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Immunis stock?
Accredited investors can buy pre-IPO stock in companies like Immunis through EquityZen funds. These investments are made available by existing Immunis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Immunis stock?
Shareholders can sell their Immunis stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."